Intellia Therapeutics (NTLA) Net Cash Flow (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Net Cash Flow for 12 consecutive years, with -$17.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 68.01% year-over-year to -$17.5 million; the TTM figure through Mar 2026 stood at $1.9 million (up 105.12% YoY), while the FY2025 annual figure was -$35.2 million, up 6.25% from the prior year.
• Net Cash Flow advanced to -$17.5 million in Q1 2026 per NTLA's latest filing, from -$39.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $385.7 million in Q4 2022 and bottomed at -$229.4 million in Q1 2023.
• Historically, Net Cash Flow has averaged $1.4 million across 5 years, with a median of -$6.9 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow sank 1629.85% — and 2025, when it jumped 459.45%.
• Intellia Therapeutics' Net Cash Flow stood at $385.7 million in 2022, then tumbled by 84.61% to $59.4 million in 2023, then rose by 15.7% to $68.7 million in 2024, then plunged by 157.91% to -$39.8 million in 2025, then surged by 56.08% to -$17.5 million in 2026.
• Business Quant data shows NTLA's Net Cash Flow at -$17.5 million in Q1 2026, -$39.8 million in Q4 2025, and $37.2 million in Q3 2025.